Earnings call Recursion delivered a strong Q3 2025, ending with $785 million in cash (as of October 9), providing runway through 2027 without additional financing. Management reaffirmed expense ...

Recursion narrowly beat EPS expectations, signaling effective cost management. Revenue fell short by 69.44%, raising concerns about growth prospects. The company maintains a strong cash position with ...

Recursion Pharmaceuticals, Inc. recently held its earnings call, which conveyed an optimistic sentiment. The company is experiencing strong leadership transitions, maintaining a robust financial ...

Hello, everybody, and welcome to Recursion's Third Quarter 2025 (L)earnings Call. My name is Chris Gibson. I'm the Co-Founder and current CEO of Recursion, and I'm so delighted to have you all joining ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2025 Earnings Call Transcript August 5, 2025 Recursion Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.41187 EPS, ...

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.